Agents against common colds, SARS and other coronaviral diseases
Human coronaviruses (HcoV) are the major cause of diseases of the upper respiratory tract in humans. Apart from the common cold these include e.g. the life-threatening severe acute respiratory syndrome (SARS), that, originating in China, has appeared in other parts of the world with a mortality rate of 15%. A key enzyme for the replication cycle of the coronavirus is the HcoV proteinase Mpro. The functional relevance of Mpro makes it an attractive target for the development of drugs against SARS and other coronaviral diseases.
The present invention relates to a group of anticoronaviral agents whose functional mechanism is based on the specific blockade of the substrate binding site of HCoV Mpro. In vitro test systems have shown the substances according to the invention to be highly effective against several coronaviruses.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Tackling Life-Threatening Fungal Infections Using RNA Modifications
Importance of RNA modifications for the development of resistance in fungi raises hope for more effective treatment of fungal infections. An often-overlooked mechanism of gene regulation may be involved in…
Unraveling Aphasia: Global Study Breaks Down Patients’ Struggle with Verb Tenses
An international team of researchers, including scientists from the HSE Centre for Language and Brain, has identified the causes of impairments in expressing grammatical tense in people with aphasia. They discovered…
Facing the Storm: A Prepped Up Future Against Extreme Climatic and Weather Changes
From the persistent droughts of southern Africa and Central America in the early part of the year to the more recent devastating extreme rainfall in Spain and the deadly Hurricane…